SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ABV-1519

ABVC·ABVC BIOPHARMA, INC.
BEARISH
Drug Impact Rating2/10
Trial phase
Phase 1 (IND cleared, no reported enrollment)
Time to market
ABV-1519 has not yet reported Phase 1 trial initiation or enrollment. Assuming the program is active, a potential approval would be many years away, contingent on completing Phase 1, Phase 2, and Phase 3 trials, which typically take 5-10 years for oncology drugs. Given ABVC's financial distress, the timeline is highly uncertain.
Why 2/10
No hard, dated catalyst is scheduled for ABV-1519 in the next 12 months. The drug received FDA IND clearance in January 2023 but no clinical data, enrollment update, or regulatory milestone has been announced since. ABV-1519 is a minor, early-stage oncology program within a financially distressed micro-cap company, so its impact on ABVC's share price is minimal relative to the company's liquidity crisis and other pipeline assets.
Actionable Insight BEARISH

ABV-1519 has no publicly announced clinical data or upcoming catalyst. The next meaningful event would be any update on patient enrollment or data from the Phase 1 study, but none has been scheduled or disclosed. The drug's fate is tied to ABVC's ability to survive as a going concern given its $11,294 cash position as of September 30, 2026.

Price Chart

Loading chart...

Executive Summary

ABV-1519 is an early-stage oncology drug candidate from ABVC BioPharma (NASDAQ: ABVC) being developed for non-small cell lung cancer (NSCLC). The FDA cleared an Investigational New Drug (IND) application in January 2023, allowing the company to proceed with clinical studies, but no patient enrollment, dosing data, or results have been publicly reported since. ABV-1519 is part of a broader oncology pipeline that was included in a global licensing term sheet in April 2024. However, ABVC is a micro-cap company in severe financial distress with only $11,294 in cash as of September 30, 2026, a going concern warning, and zero product revenue. With no upcoming catalyst and no clinical progress visible, ABV-1519 is a stalled, early-stage program at a company fighting for survival.

How It Works

ABV-1519 is an investigational oncology drug candidate being developed for the treatment of non-small cell lung cancer (NSCLC). Its specific mechanism of action has not been publicly detailed by the company, but it is part of ABVC's oncology/hematology pipeline of botanical-derived or small-molecule therapeutics targeting solid tumors.

Trial Status

The FDA approved an IND for ABV-1519 in January 2023 for a clinical study in non-small cell lung cancer. No subsequent updates on patient enrollment, dosing, or results have been publicly disclosed. No ClinicalTrials.gov record was found for this specific drug candidate.

The Two-Sided Case

▲ Bull Case4
The FDA cleared an IND for ABV-1519 in January 2023, allowing ABVC to proceed with a clinical study in non-small cell lung cancer, a large oncology market with high unmet need.
ABVC executed a global licensing term sheet for its oncology/hematology portfolio (including ABV-1519) in April 2024, expecting up to $55 million in licensing income and up to $50 million in royalties, which could provide non-dilutive funding.
Institutional investors showed accumulation in Q3 2026: UBS doubled its position, State Street and Vanguard Capital added shares.
ABVC's licensing-first business model has generated some milestone revenue ($1.28 million in Q3 2025), demonstrating a path to monetize pipeline assets without bearing full development costs.
▼ Bear Case5
ABVC had only $11,294 in cash as of September 30, 2026, with a $5.79 million working capital deficit and a going concern warning, making it unclear how the company can fund any clinical trial for ABV-1519.
No clinical trial results, patient enrollment data, or ClinicalTrials.gov record have been publicly reported for ABV-1519 since the FDA IND clearance in January 2023, suggesting the program may be stalled or deprioritized.
ABVC has zero product revenue and relies on dilutive convertible note financings (most recently $3.39 million gross in October 2026), creating severe shareholder dilution risk.
Analyst consensus on ABVC is bearish: 0 buy, 3 hold, 1 sell, 0 strong buy, 2 strong sell ratings.
ABV-1519 is one of several early-stage oncology candidates (alongside ABV-1703, ABV-1501) at a company whose more advanced pipeline focuses on CNS and ophthalmology, making it a minor program unlikely to drive near-term value.

Upcoming Catalysts

  • No scheduled catalysts identified. Any future catalyst would depend on ABVC providing a clinical update, initiating patient enrollment, or announcing a licensing/sub-licensing deal for ABV-1519.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report

Sources · 2

Hover a chip for the title
1 markets.financialcontent.com2 sec.gov